Pre-made Besilesomab benchmark antibody (Radiolabelled antibody, anti-CEACAM8/NCA-95 therapeutic antibody, Anti-CD66b/CD67/CGM6 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Besilesomab?(trade name?Scintimun) is a?mouse?monoclonal antibody?labelled with the radioactive isotope?technetium-99m. It is used to detect inflammatory lesions and?metastases.[1]?It binds to an?immunoglobulin, IgG1?isotype. SCINTIMUN has been used since 1992 mainly in Hungary, Czech Republic, and Switzerland on the basis of local marketing authorizations, and in Germany (on the basis of individual prescription). Between 1992 and 2009, an estimated 90,000 patients has been studied. In 2009, the?EMEA?has approved SCINTIMUN for marketing in all European countries.[